The Tel Aviv-based firm develops powder-based Intranasal specialised therapies.
Israeli firm Nasus Pharma (NYSE: NSRX), which develops powder-based Intranasal specialised therapies, has introduced the completion of its IPO, elevating $10 million at an organization valuation of $75 million, after cash. Laidlaw & Firm (UK) Ltd. and Craft Capital Administration LLC are performing as joint book-runners for the providing.
This has been a uncommon pharmaceutical flotation in current months, after the sector has seen share costs constantly fall since 2021. There have additionally been few IPOs of Israeli firms in recent times.
Nasus was based in 2019 by VP improvement Dr. Dalia Megiddo and chairman Udi Gilboa, who’ve beforehand held flotations for Alcobra and Bioblast. Dan Teleman is CEO of Nasus. Based on the prospectus, Nasus solely has two staff.
NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free different to Epinephrine auto-injectors for sufferers with anaphylaxis. Intranasal administration is most fitted for these conditions during which fast drug supply is required and presents needle free, straightforward to make use of alternate options. Nasus proprietary powder-based intranasal (“PBI”) know-how is designed for fast and dependable drug supply, leveraging the nasal cavity’s wealthy vascular community for fast absorption. The PBI formulation makes use of uniform spherical powder particles for broad dispersion and probably sooner, greater absorption in comparison with liquid-based nasal merchandise.
Revealed by Globes, Israel enterprise information – en.globes.co.il – on August 13, 2025.
© Copyright of Globes Writer Itonut (1983) Ltd., 2025.
